益气活血通络法治疗慢性阻塞性肺疾病D组稳定期的临床观察

发布时间：2018-01-08 03:22

本文关键词：益气活血通络法治疗慢性阻塞性肺疾病D组稳定期的临床观察　出处：《中华中医药学刊》2017年06期 　论文类型：期刊论文

【摘要】：目的:观察益气活血通络法对慢性阻塞性肺疾病(COPD)综合评估分级为D组稳定期气虚痰瘀型患者的临床症状、肺功能及CAT评分的影响。方法:将40例COPD稳定期(D级)患者随机分为治疗组(20例)和对照组(20例),治疗组采用吸人沙美特罗氟替卡松粉吸入剂50/500μg联合口服中药保肺定喘汤,对照组采用吸人沙美特罗氟替卡松粉吸人剂50/500μg,治疗3月后,评价两组患者临床症状积分、肺功能和CAT评分。结果:(1)治疗后两组患者症状积分比较具有统计学意义(P=0.002);(2)治疗后各项肺功能指标组间比较无统计学差异(P均0.05);(3)治疗后治疗组患者CAT评分优于对照组,差异具有统计学差异(P=0.018)。结论:慢性阻塞性肺疾病D组稳定期运用益气活血通络法治疗可以改善气虚痰瘀型患者临床症状和生活质量。
[Abstract]:Objective: To observe the effect of Yiqi Huoxue Tongluo method on chronic obstructive pulmonary disease (COPD) is a comprehensive assessment and classification of clinical symptoms in patients with stable D group of qi deficiency and phlegm stasis type, pulmonary function and CAT scores. Methods: 40 patients with stable COPD (D grade) were randomly divided into treatment group (20 cases) and the control group (20 cases), treatment group with inhaled fluticasone propionate Shah Mette Lo 50/500 g combined with oral Chinese medicine Baofei Dingchuan decoction, the control group using suction Shah Mette Lo fluticasone inhalation treatment agent 50/500 g, after March, evaluation of two groups of patients with clinical symptom score, CAT score and pulmonary function. Results: (1) the two groups after treatment symptom scores was statistically significant (P=0.002); (2) after the treatment of pulmonary function indexes no statistically significant difference between the groups (P 0.05); (3) after treatment with CAT score than the control group, a statistically significant difference (P=0.018) conclusion: The clinical symptoms and quality of life of patients with Qi deficiency and phlegm stasis can be improved by using the therapy of Supplementing Qi and activating blood and dredging collaterals in the stable period of chronic obstructive pulmonary disease (D).

【作者单位】：浙江中医药大学附属中西医结合医院;
【基金】：国家自然科学基金项目(81403336)
【分类号】：R259
【正文快照】： 慢性阻塞性肺疾病(COPD)是呼吸系统常见病,多发病,中国40岁以上人群中平均患病率8.2%[1],其病情不断进展最终可引起呼吸衰竭和肺源性心脏病,已是造成老年人致残和死亡的主要原因之一。目前全球因COPD死亡人数约300万,居世界死亡原因第4位,至2020年,COPD将成为世界第三大死亡原

【相似文献】